Featured by Newsweek & World Class Media Outlets

Interviews

Industry

Julie Ross
Julie Ross
President and CEO
Advanced Clinical
2024-02-22

Ensuring that trial participants reflect the demographic of the disease leads to more effective drugs and a better understanding of how responses vary across different regions and demographics.

READ MORE
Michael Davidson
Michael Davidson
MD & CEO
New Amsterdam Pharma
2024-02-22

Today, more than 70% of patients with high cholesterol are not meeting their treatment goals.

READ MORE
Jay Lichter
Jay Lichter
President & CEO
Arialys Therapeutics
2024-02-21

Our primary challenge is navigating the regulatory landscape, as there is no FDA approved treatment for ANRE.

READ MORE
Debbie Hart
Debbie Hart
President & CEO
BioNJ
2024-02-21

Notably, companies in New Jersey were responsible for more than 50% of all novel FDA drug approvals in 2023, a testament to our leadership in this field.

READ MORE
Emil Kakkis
Emil Kakkis
CEO
Ultragenyx Pharmaceutical
2024-02-20

Our approach at Ultragenyx has been to streamline the drug development process, making it faster and more cost-efficient.

READ MORE
Andrew Casey
Andrew Casey
President & CEO
BIOTECanada
2024-02-20

So, while AI might reduce the need for certain traditional roles, it simultaneously creates a demand for new types of expertise.

READ MORE
E. Anders Kolb
E. Anders Kolb
M.D., President & Chief Executive Officer
The Leukemia & Lymphoma Society (LLS)
2024-02-19

One of the unintended consequences of innovation is that we are creating a multi-tiered system of healthcare in the US that prevents access to care.

READ MORE
Dr. Trevor P. Castor
Dr. Trevor P. Castor
President & CEO
Aphios Corporation
2024-02-16

The essence of our platform's value lies in its ability to generate products, such as Zindol, being developed for chemotherapy-induced nausea and vomiting.

 

READ MORE
Lisa Moneymaker
Lisa Moneymaker
CTO & CPO
Saama
2024-02-12

Saama focuses on the core operational management of clinical trials, positioned between molecule discovery and post-market commercial analysis.

READ MORE
Mark Goldberg
Mark Goldberg
Chairman & CEO
Allucent
2024-02-12

Allucent’s approach is unique in its comprehensive and expert-driven services. We do not just offer operational assistance; we also provide strategic guidance to maximize the success likelihood of our clients' projects.

READ MORE